Roche Holding Ltd · SIX:RO
Roche — H1 2025 Earnings Presentation
75 slides from Roche's earnings presentation, Jul 24, 2025
Slide 1: Slide 1
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Roche HY 2025 results
Roche HY 2025 results Basel, 24 July 2025
Slide 4: Group
Group Thomas Schinecker Chief Executive Officer
Slide 5: Performance Outlook
Performance Outlook
Slide 6: HY 2025: Strong financial performance
HY 2025: Strong financial performance HY results all at CER ▪ Group sales growth +7%, +10% Pharma and 0% for Diagnostics (due to China healthcare pricing reforms) ▪ Strong bottom line performance with Core OP +11% and Core OP margin +1.1%p; Core EPS +12% ▪ Full year LOE impact expectation lowered to
Slide 7: HY 2025: Strong Pharma sales driving Group growth
HY 2025: Strong Pharma sales driving Group growth Diagnostics impacted by healthcare pricing reforms in China HY 2025 HY 2024 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 24.0 22.6 6 10 Diagnostics Division 7.0 7.2 -3 0 Roche Group 30.9 29.8 4 7 Totals & sub-totals may include difference
Slide 8: HY 2025: Consistent strong growth in the last five quarters
HY 2025: Consistent strong growth in the last five quarters Diagnostics impacted by healthcare pricing reforms in China; impact expected to ease towards year-end Group sales growth %CER +15% China Diagnostics healthcare pricing reforms +10% +9% +9% +9% +9% +8% +6% +5% +2% +1% +2% +1% 0% COVID-19 pan
Slide 9: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio All therapeutic areas delivering strong growth; Diagnostics impacted by healthcare pricing reforms in China Diagnostics: Molecular Lab and HY 2025 sales Pathology Lab with strong growth; Core 0% (CHFbn, YoY CER growth) Lab impacted by China healthcare pricin
Slide 10: Young portfolio to drive growth in the near- to mid-term
Young portfolio to drive growth in the near- to mid-term 3 key pivotal NME readouts remaining in 2025 CHFbn % of Pharma Sales2 59% 14.0 55% 12.0 50% 10.0 41% 8.0 1 6.0 4.0 2.0 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.0 HY 2022 HY 2023 HY 2024 HY 2025 Pivotal NME readouts Cotellic Ale
Slide 11: Performance Outlook
Performance Outlook
Slide 12: Roche Diagnostics Day highlights
Roche Diagnostics Day highlights Key innovative solutions across our customer areas AXELIOS NGS solution Accu-Chek® SmartGuide cobas® i601 Mass Spec VENTANA® TROP2 RxDx1 Molecular Lab Near Patient Care Core Lab Pathology Lab ▪ New data demonstrate high ▪ 14 day real-time glucose ▪ First fully integr
Slide 13: 2025 Pharma pipeline: Q2 newsflow
2025 Pharma pipeline: Q2 newsflow New Molecular Entities (NME) giredestrant fenebrutinib vamikibart HR+ BC RMS, PPMS DME, UME Itovebi Elevidys1 CT-388 Pi3Km BC DMD Obesity +/- T2D divarasib Emugrobart (GYM 329) CT-868 KRAS+ NSCLC, CRC SMA, FSHD, obesity T1D with BMI ≥25 ▪ 7+ NMEs with CHF >3bn peak
Slide 14: Ph III Go decisions taken so far in 2025
Ph III Go decisions taken so far in 2025 4 Ph III Go-decisions so far, including prasinezumab in PD and NXT007 in Hemophilia A NXT007 in Trontinemab Prasinezumab Zosurabalpin Hemophilia A in Alzheimer’s disease in Parkinson’s disease in MDR bacterial infections Oncology/Hematology Neurology Neurolog
Slide 15: R&D Excellence: Pipeline evolution
R&D Excellence: Pipeline evolution Growing share of potential best in disease assets and increasing peak sales for pipeline projects Share of late-stage projects with BID potential1 Average peak sales per pipeline project, CHFbn2 +55% +9%p 1.3 Total 0.8 portfolio value 67% +26% 58% YE 2023 HY 2025 Y
Slide 16: R&D Excellence: Resource reallocation
R&D Excellence: Resource reallocation CHF ~1bn spend reallocated to transformative programs and productivity initiatives Reallocation of the R&D budget in 2024+20251 (CHFm) Reinvestment into the portfolio 1,050 1,050 ▪ Increased the number of high value assets 610 ▪ Fast tracked key assets, includin
Slide 17: 2025 guidance
2025 guidance LOE impact of CHF 1.0bn (CER, updated from CHF 1.2bn) expected for 2025 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1. At CER: Constant exchange rates (avg. full year 202
Slide 18: Finance
Finance Alan Hippe Chief Financial Officer
Slide 19: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook
Slide 20: HY 2025: Group performance
HY 2025: Group performance Sales increase of +7% and core EPS increase of +12% 2025 2024 Change in % CHFm CHFm CHF CER Sales 30,944 29,848 +4 +7 Core operating profit 12,010 11,293 +6 +11 as % of sales 38.8 37.8 Core net income 9,319 8,651 +8 +13 as % of sales 30.1 29.0 Core EPS (in CHF) 11.08 10.23
Slide 21: HY 2025: Group sales growth at +7%
HY 2025: Group sales growth at +7% Pharma driving growth; Diagnostics stable, growth impacted by healthcare pricing reforms in China +7% at CER CHFm +2,492 -347 -1,071 +348 -326 30,944 29,848 HY 2024 YTD PY China dia ex. Cn Dia biz dia base Pharma Pharma Underlying LOE LOE sales Fx Fx HY 2025 YTD CY
Slide 22: HY 2025: Group core operating profit
HY 2025: Group core operating profit Core operating profit higher by +11% driven by higher sales and effective cost management 2025 2025 vs. 2024 CHFm Abs. CERm CER growth Sales 30,944 +2,166 7% Other revenue 905 +15 2% Cost of sales -7,562 -588 8% Sales volume: +12% R&D -6,074 +66 -1% SG&A -6,508 -
Slide 23: HY 2025: Core operating profit and margin
HY 2025: Core operating profit and margin % of sales 50.4% 52.2% 37.8% 38.8% +1.7%p¹ +1.1%p¹ 22.0% +13%¹ 18.0% CHFm +11%¹ 12,522 -3.2%p¹ 12,010 11,293 11,409 -14%¹ 2024 2025 1,583 1,250 Roche Group Pharma Division Diagnostics Division Note: Group core operating profit includes -1.8bn from Corporate
Slide 24: HY 2025: Core net financial result
HY 2025: Core net financial result Improvement mainly driven by lower losses from net foreign exchange results (Other) CHFm ▪ Net financial result improved by +84m / -10% at CER ▪ Interest expenses1 stable at CER -729 -838 +161 0 +20 -72 HY 2024 Equity Net interest Interest Other HY 2025 securities
Slide 25: HY 2025: Core tax rate
HY 2025: Core tax rate Tax rate stable compared to HY 2024 17.3% +0.1%p 17.4% 19.0% Effective tax rate Effective tax rate HY 2024 HY 2025 25
Slide 26: HY 2025: Core EPS
HY 2025: Core EPS Increase in operations partially offset by lower gains on product disposals +12.1% + 14.4%p + 0.1%p + 0.5%p 11.56 - 2.5%p - 0.4%p 10.31 HY 2024 Operations1 Product disposals Financial Effective tax All other effects HY 2025 & disposal of income/expense rate change subsidiaries All
Slide 27: HY 2025: Non-core and IFRS income
HY 2025: Non-core and IFRS income Non-core items down vs. PY mainly due to lower impairment of intangible assets 2025 2024 Var. at Change in % CHFm CHFm CERm CHF CER Core operating profit 12,010 11,293 +1,195 +6 +11 Global restructuring plans -1,023 -762 -278 Amortisation of intangible assets -348 -
Slide 28: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook
Slide 29: HY 2025: Group operating free cash flow
HY 2025: Group operating free cash flow OFCF down by -20% mainly driven by investments in IA (including the Zealand Pharma collaboration) CHFm +1,039 -1,421 -38 -1,194 -195 7,923 OFCF down by -20%/-1,614m at CER 6,309 6,114 HY 2024 OP, net of cash NWC Investments Investments HY 2025 Foreign HY 2025
Slide 30: HY 2025: Operating free cash flow and margin
HY 2025: Operating free cash flow and margin % of sales 42.6% 35.6% 27.0% 19.8% -7.1%p¹ -7.0%p¹ 6.8% -3.3% CHFm -9.3%p¹ -9%¹ 9,647 8,533 8,053 -20%¹ 6,114 2024 2025 491 -¹ -232 Roche Group Pharma Division Diagnostics Division Note: Group operating free cash flow includes -2.2bn from Corporate (-2.1b
Slide 31: HY 2025: Group net debt development
HY 2025: Group net debt development Net debt higher by CHF 3.7bn vs. YE 2024 CHFbn Free cash flow CHF +3.3 -17.3 Dividends paid -7.9 -21.0 Trans. own eq. inst. -0.5 -2.8 M&A & all. trans. -0.9 Curr. transl. & oth. +2.4 +6.1 Taxes -2.2 Treasury -0.6 -6.9 Net debt Operating Non-operating Dividends, M&
Slide 32: Balance sheet 30 June 2025
Balance sheet 30 June 2025 Equity ratio at 35% (31 Dec 2024: 36%, 30 Jun 2024: 34%) % change in CER % change in CER CHFbn vs. 31 Dec 2024 vs. 31 Dec 2024 101.8 0% 101.8 0% Cash and 94.8 94.8 marketable 17.3 -28% securities 12.0 Current 27.0 17% 13% 27% 27.6 +9% liabilities Other 22.7 29% 23.7 +11% c
Slide 33: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook
Slide 34: Exchange rate impact on sales growth
Exchange rate impact on sales growth Negative impact mainly driven by the USD, EUR and CNY (APAC) -0.3%p -0.5%p -1.5%p CER -0.8%p CHF 0.0%p sales growth sales growth 2025 +7.3% 2025 vs. -0.5%p vs. 2024 2024 +3.7% CER EUR APAC USD LATAM JPY Other CHF CER: Constant exchange rates (avg. full year 2024)
Slide 35: Expected 2025 currency impact
Expected 2025 currency impact USD / CHF Assumed avg. YTD 2025 +3% -3% -4% -6% Assuming the 30 June 2025 exchange rates remain stable 0.90 0.89 until end of 2025, 0.88 0.88 2025 impact1 is expected to be (%p): 0.87 0.86 0.84 0.83 Q1 Q2 Q3 Q4 0.91 0.90 0.88 0.84 0.83 0.82 0.80 0.80 0.80 0.80 0.80 0.80
Slide 36: 2025 guidance
2025 guidance LOE impact of CHF 1.0bn (CER, updated from CHF 1.2bn) expected for 2025 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1. At CER: Constant exchange rates (avg. full year 202
Slide 37: Board proposes exchange of Genussscheine for participation certificates
Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine) Current structure Future structure: Subject to approval at the AGM 2026 13.2% 13.2% 106,691,000 bearer shares 106,691,000 bearer shares (nominal value CHF 1.00 each) (nominal value CH
Slide 38: Pharmaceuticals Division
Pharmaceuticals Division Teresa Graham CEO Roche Pharmaceuticals
Slide 39: HY 2025: Pharmaceuticals sales
HY 2025: Pharmaceuticals sales Strong growth across all regions HY 2025 HY 2024 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 23,985 22,637 6 10 United States 12,670 11,882 7 10 Europe 4,566 4,425 3 5 Japan 1,425 1,366 4 5 International 5,324 4,964 7 ##### 14 CER: Constant exchange rates (a
Slide 40: HY 2025: Pharmaceuticals core operating profit
HY 2025: Pharmaceuticals core operating profit Core operating profit outgrowing sales with +13%, driven by higher sales and effective cost management 2025 2025 vs. 2024 CHFm Abs. CERm CER growth Sales 23,985 +2,145 10% Other revenue 870 +1 0% Cost of sales -4,119 -321 8% R&D -5,181 +46 -1% SG&A -3,2
Slide 41: HY 2025: Young portfolio delivering strong growth
HY 2025: Young portfolio delivering strong growth Phesgo, Xolair, Hemlibra, Vabysmo, Ocrevus and Polivy driving growth Phesgo 55% Xolair 34% Hemlibra 17% Vabysmo 18% Ocrevus 8% Polivy 46% Xofluza 185% Elevidys 316% Alecensa 8% Evrysdi 7% Gazyva 14% Columvi 88% Actemra / RoActemra 4% Enspryng 27% Ito
Slide 42: Oncology/Hematology
Oncology/Hematology Oncology growing +2% driven by the HER2+ franchise New data presented for Perjeta, Itovebi and Tecentriq Q2 update Itovebi Avastin CHF 36m / N/A ▪ Phesgo: Strong uptake across all regions CHF 522m / -17% Others ▪ EU: Positive CHMP opinion for admin outside of hospital Herceptin C
Slide 43: HER2+ franchise: Continued strong Phesgo and Kadcyla growth
Oncology/Hematology HER2+ franchise: Continued strong Phesgo and Kadcyla growth Phesgo: First mAb-based BC treatment with the flexibility to be administered outside of the hospital (incl. at-home) Global Phesgo conversion rate* HER2+ BC treatment paradigm evolving 50% ** Neoadjuvant Adjuvant cont. F
Slide 44: HER2+ franchise: Evolving mBC treatment paradigm
Oncology/Hematology HER2+ franchise: Evolving mBC treatment paradigm Roche HER2+ portfolio well-positioned to meet evolving needs No “one size fits all” in 1L mBC Oncologist insights from ASCO1 91% believe in using T-Dxd for induction 80% consider using P+H or Phesgo Recent study readouts in Breast
Slide 45: Polivy US patient share in 1L DLBCL reaching 33%
Oncology/Hematology Polivy US patient share in 1L DLBCL (IPI 0-5) reaching 33% Hemlibra with strong growth across all patient segments and regions Q2 update Lunsumio Columvi CHF 48m / +33% ▪ Hemlibra: Increasing adoption in non-inhibitor patients as key CHF 123m / +88% PiaSky global growth driver CH
Slide 46: NXT007: Ph I/II results indicate best-in-disease potential
Oncology/Hematology NXT007: Ph I/II results indicate potential for best-in-disease efficacy No treated bleeds in cohorts B-3 and B-4 during NXT007 prophylaxis; Ph III program to initiate in 2026 Ph I/II (NXTAGE Part B) in Hemophilia A: Results1 Clinical development 14 Mean ABR for treated bleeds2 12
Slide 47: Ocrevus Zunovo: 50% of new patients naïve to Ocrevus
Neurology Ocrevus Zunovo: 50% of new patients in US are naïve to Ocrevus Achieved EU approval for Evrysdi tablet formulation Q2 update ▪ Ocrevus: >6,800 patients on Ocrevus SC globally Elevidys Others CHF 117m / +316% ▪ Evrysdi: EU approval for tablet formulation achieved CHF 203m / -1% Enspryng ▪ E
Slide 48: Prasinezumab: Moving into Ph III in Parkinson's disease
Neurology Prasinezumab: Moving into Ph III in Parkinson’s disease Ph IIb (PADOVA) and longer follow-up data suggest clinical benefit in delay of confirmed motor progression Prasinezumab (α-synuclein Ab) Ph IIb (PADOVA) 2.5 years results3 Change from baseline to Week 132 on MDS-UPDRS Part III OFF (L-
Slide 49: Prasinezumab Ph III Go decision based on meeting the Bar criteria
Neurology Prasinezumab Ph III Go decision based on meeting the Bar criteria Insights from Ph IIb (PADOVA) and open label extension will inform Ph III trial design The Bar Prasinezumab Answers a clear & addressable ▪ >10m PD patients globally with no approved DMT to slow/stop unmet need progression ▪
Slide 50: Xolair food allergy launch with continued strong momentum
Immunology Xolair food allergy launch with continued strong momentum Astegolimab in COPD with mixed results Q2 update ▪ Xolair: Strong food allergy launch with >60k patients on treatment Others CHF 454m / 0% Actemra ▪ Biosimilar launch expected end of 2026 CHF 1,279m / +4% ▪ Actemra: Biosimilar laun
Slide 51: Vabysmo with continued strong growth momentum
Ophthalmology Vabysmo with continued strong growth momentum Growth delivered despite expected branded market contraction in US Q2 update Luxturna CHF 36m / +292% Susvimo ▪ Vabysmo: Continued market share gains across early launch Lucentis CHF 4m / +335% countries and ongoing global expansion CHF 41m
Slide 52: CVRM pipeline progressing
Cardiovascular, Renal & Metabolism CVRM pipeline progressing Additional trial readouts and Ph III initiations expected for 2025 Clinical development Q2 update ▪ CT-388: Additional Ph I data presented at ADA Indication Asset Ph I Ph II Ph III ▪ Cohort 12: Effect of CT-388 on liver fat ▪ Cohort 13: CT
Slide 53: 2025: Significant key newsflow ahead
2025: Significant key newsflow ahead* Compound Indication Milestone Itovebi + palbociclib + fulvestrant 1L PIK3CA-mut HR+ BC EU approval Columvi + GemOx 2L+ DLBCL US/EU approval / (US/EU) Lunsumio SC 3L+ FL US approval/EU filing (EU filing) Elevidys DMD EU approval Regulatory Gazyva Lupus nephritis
Slide 54: Invitation to Roche Pharma Day 2025
Invitation to Roche Pharma Day 2025 Morning session (Pharma strategy & business; R&D Excellence): ▪ Pharma strategy and commercial growth drivers Teresa Graham, CEO Roche Pharmaceuticals ▪ R&D Excellence update Levi Garraway, CMO and Global Head of PD Afternoon session (pipeline updates): ▪ Oncology
Slide 55: Diagnostics Division
Diagnostics Division Matt Sause CEO Roche Diagnostics
Slide 56: HY 2025: Diagnostics sales
HY 2025: Diagnostics sales Diagnostics Division stable, growth impacted by healthcare pricing reforms in China HY 2025 HY 2024 Change in % CHFm CHFm CHF CER Diagnostics Division 6,959 7,211 -3 0 Core Lab 3,839 4,072 -6 -2 Molecular Lab 1,250 1,257 -1 3 Near Patient Care 1,018 1,094 -7 -3 Pathology L
Slide 57: HY 2025: Diagnostics highlights
HY 2025: Diagnostics highlights Diagnostics Division stable, growth impacted by healthcare pricing reforms in China CHFbn YoY CER growth ▪ Immunodiagnostics (-5%) Core Lab -2% ▪ Clinical Chemistry (+5%) ▪ Infectious diseases (-1%) +3% Molecular Lab ▪ Blood Screening (+8%) Near Patient ▪ BGM (-4%) -3
Slide 58: HY 2025: Diagnostics regional sales
HY 2025: Diagnostics regional sales Strong growth in Latin America, North America and EMEA North America +6% EMEA ~32% of divisional sales +5% ~36% of divisional sales Asia Pacific Latin America -15% +14% ~25% of divisional sales ~7% of divisional sales Growth rates at constant exchange rates (avg.
Slide 59: HY 2025: Diagnostics core operating profit
HY 2025: Diagnostics core operating profit Core operating profit lower by -14% driven by China healthcare pricing reforms 2025 2025 vs. 2024 CHFm Abs. CERm CER growth Sales 6,959 +22 0% Other revenue 35 +14 67% Cost of sales -3,443 -267 8% R&D -893 +20 -2% SG&A -1,429 +7 0% OOI&E 21 -14 -39% Core op
Slide 60: AXELIOS: Roche Sequencing solution
AXELIOS: Roche Sequencing solution New data demonstrate high speed and accuracy across multiple clinical applications Whole Genome Sequencing with FFPE sample analysis in oncology Minimal residual disease in oncology SBX-Fast1 TMB [mut/Mbps] Homopolymer accuracy Colour One SBX-D (No Amp) Cancer ctDN
Slide 61: Elecsys PRO-C3 CE mark
Cardiometabolic Elecsys® PRO-C3 CE mark Elecsys® PRO-C3 together with ADAPT algorithm will advance management of liver fibrosis Elecsys® PRO-C3 Market opportunity ▪ High Disease Burden: MASLD affects 30% of the population, and remains asymptomatic in most patients until advanced stages2 Patients wit
Slide 62: Elecsys Pepsinogen I/II JSMPA approval
Elecsys® Pepsinogen I/II JSMPA approval Elecsys® Pepsinogen I/II will enable screening and triage for patients at high risk of atrophic gastritis Elecsys® Pepsinogen I/II Market opportunity ▪ High Disease Burden: China accounts for 40% (~360k) of new global gastric cancer cases; atrophic gastritis i
Slide 63: VENTANA TROP2 RxDx FDA BDD
Oncology VENTANA® TROP2 RxDx FDA BDD First AI-driven companion diagnostic for non-small cell lung cancer VENTANA® TROP2 RxDx1 Market opportunity ▪ High Disease Burden: Lung cancer affects ~2.5m new patients/year; 80% have NSCLC2 ▪ TROP2 is broadly expressed in NSCLC tumours; quantifying its expressi
Slide 64: Diagnostics key launches 2025
Diagnostics key launches 2025 Area Product Description Market Status Elecsys® pTau 181 Non-invasive blood-based biomarker to enable earlier detection and rule out amyloid pathology CE Elecsys® Troponin-T hs High-sensitive test with greater precision at lower measurement ranges, enabling HCPs to conf
Slide 65: Upcoming IR events
Upcoming IR events
Slide 66: IR events currently planned for 2025
IR events currently planned for 2025 Additional events driven by readouts Ophthalmology Neurology Update Diagnostics Day Hematology Update Pharma Day Update 4 Apr 27 May 23 Jun 22 Sep tbd ▪ Neurology franchise ▪ Deep-dive into the ▪ Hematology franchise ▪ Update on Pharma ▪ Ophthalmology franchise u
Slide 67: Doing now what patients need next
Doing now what patients need next
Slide 68: Changes to the development pipeline
Changes to the development pipeline Q2 2025 update New to phase I New to phase II New to phase III New to registration 2 NMEs: 1 AI: 1 AI (US): RG6505 PanRAS inhibitor – solid tumors RG6237 emugrobart (GYM 329) – obesity RG7446 Tecentriq + lurbinectedin – RG6327 NME - geographic atrophy 1L maintenan
Slide 69: Roche Group development pipeline
Roche Group development pipeline Phase I (42 NMEs + 7 AIs) Phase II (18 NMEs + 8 AIs) RG6026 Columvi monotherapy + combos heme tumors CHU CD137 switch solid tumors RG6107 PiaSky sickle cell disease RG6076 englumafusp alfa combos heme tumors CHU paluratide (RAS inhibitor) solid tumors RG6171 giredest
Slide 70: Roche Group development pipeline
Roche Group development pipeline Phase III (7 NMEs + 28 AIs) Registration US & EU (1 NME + 4 AIs) RG3502 Kadcyla + T HER-2+ eBC high-risk RG6149 astegolimab COPD RG7446 Tecentriq + lurbinectedin1 1L maintenance SCLC Columvi + Polivy + R-CHP 1L DLBCL RG6299 sefaxersen (ASO factor B) IgA nephropathy R
Slide 71: Expected regulatory submissions
Expected regulatory submissions* New Molecular Entities: Lead and additional indications New Molecular Entity (NME) Cardiovascular, Renal & Metabolism emugrobart (GYM 329) Additional Indication (AI) Neurology RG6237 + Evrysdi Oncology / Hematology Ophthalmology SMA Immunology Other emugrobart (GYM 3
Slide 72: Expected regulatory submissions
Expected regulatory submissions* Marketed products: Additional indications New Molecular Entity (NME) Cardiovascular, Renal & Metabolism Additional Indication (AI) Neurology Oncology / Hematology Ophthalmology Immunology Other ✓ Indicates submission to health authorities has occurred Unless stated o
Slide 73: Major pending approvals 2025
Major pending approvals 2025 US EU China Japan-Chugai Xofluza Elevidys Polivy + chemo Tecentriq RG6152 influenza direct transmission RG6356 DMD (EU) RG7596 r/r DLBCL RG7446 ENKL Filed Nov 2024 Filed May 2024 Filed May 2025 Filed Oct 2024 Lunsumio SC Lunsumio SC CellCept RG7828 3L+FL RG7828 3L+FL RG9
Slide 74: Major granted approvals 2025
Major granted approvals 2025 US EU China Japan-Chugai TNKase Columvi + chemo Lunsumio Tecentriq RG3625 stroke RG6026 2L DLBCL RG7828 3L+ FL RG7446 Alveolar Soft Part Sarcoma Feb 2025 April 2024 Dec 2024 Feb 2025 Susvimo Xofluza Itovebi + palbociclib + fulvestrant Elevidys RG6321 DME RG6152 influenza
Slide 75: Doing now what patients need next
Doing now what patients need next